Skip to content

Safety and Efficacy of FLACS With the FEMTO LDV Z8 Laser Compared to Conventional Cataract Surgery in Chinese Patients

Safety and Efficacy of FLACS With the FEMTO LDV Z8 Laser Compared to Conventional Cataract Surgery in Chinese Patients

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03953053
Acronym
Z8CAT01
Enrollment
132
Registered
2019-05-16
Start date
2019-06-03
Completion date
2020-06-04
Last updated
2021-12-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cataract

Keywords

Femto Cataract Surgery

Brief summary

This trial will be designed as a multi-center randomized non-inferiority clinical trial to demonstrate safety and efficacy of the FEMTO LDV Z8 laser for cataract surgery in a Chinese population in China compared to the conventional technique.

Detailed description

In this three center, prospective, interventional, randomized controlled study we aim to determine safety and efficacy of the FEMTO LDV Z8 laser as compared to conventional technique in Chinese patients diagnosed with cataract of any severity grade that are eligible to undergo cataract surgery with age 50 years and a maximum age of 80 years in China.

Interventions

DEVICEFemtosecond Laser Assissted Cataract Surgery

During routine Catarct Surgery the Femtolaser cuts a ACCC (Anterior Continous Curvilinear Capsulotomy) into the lensbag and fragmentise the cataract affilited lens body

Sponsors

Ziemer Ophthalmic Systems AG
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
50 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Eligible to undergo cataract extraction by phacoemulsification with primary intraocular lens implantation * Provision of signed and dated informed consent form * Male or female, between 50 and 80 years of age (50 and 80 are included). * IOL chosen for implantation a monofocal aspheric IOL of 6mm optic diameter * Willing to comply with all study procedures and able to return for scheduled follow-up examinations * Willing to adhere to the medication (to prevent inflammation and infection) regimen

Exclusion criteria

* Corneal disease or pathology, such as corneal scaring or opacity, that precludes transmission of laser wavelength or that distorts laser light * Poorly dilating pupil or other defect of the pupil that prevents the iris from adequate retraction peripherally (e.g., intraoperative floppy iris syndrome) * Glaucoma or ocular hypertension, pseudoexfoliation * Corneal endothelial pathology where endothelial cell count is compromised (Fuchs endothelial dystrophy and others) * Complicated cataract, such as traumatic, white, intumescent or posterior and anterior subcapsular cataracts * Nystagmus or hemofacial spasm preventing placement of the patient interface * Previous intraocular or corneal surgery of any kind, including any type of surgery for either refractive or therapeutic purposes in either eye * Allergy to medications required in surgery, pre- and post-operative treatment * History of lens or zonular instability * Keratoconus or keratectasia * Immune compromised or diagnosis of ophthalmic disease: ocular herpes zoster or simplex, lupus, collagenosis and other acute or chronic illnesses that increases the risk to the subject or confounds the outcomes of this study in the opinion of the study PI (Principal Investigator) * Anterior chamber depth (ACD) \< 1.5 mm or \> 4.8 mm as measured from the corneal endothelium. * Developmental disability or cognitive impairment that would make informed consent and the assessment of visual acuity impossible * Concurrent participation in another ophthalmological clinical study

Design outcomes

Primary

MeasureTime frameDescription
Endothelial cell loss4 monthTo determine whether the FLACS with the FEMTO LDV Z8 laser is non-inferior to measured using the NSP 9900, KONAN MEDICAL, and calculated according to: postoperative endothelial cell loss = preoperative endothelial count - postoperative endothelial cell count

Secondary

MeasureTime frameDescription
Cumulative dissipated energy (CDE)4 monthRecording of CDE on Phaco device
Ultrasound (US) total time4 monthRecord of US Energy applied
Estimated fluid usage (EFU)4 monthRecord of EFU
Intra- and post- surgical complications4 monthDiagnosis of Complications in combination with usual follow-up measures
Uncorrected distance visual acuity (UDVA)4 monthMeasurement of UDVA
Corrected distance visual acuity (CDVA)4 monthMeasurement of CDVA
Corneal thickness (CCT)4 monthMesurement of the Central Corneal Thickness

Countries

Switzerland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 10, 2026